NASDAQ:TXG

10x Genomics Stock Forecast, Price & News

$179.67

-0.22 (-0.12 %)

(As of 01/15/2021 12:00 AM ET)

Add

Compare

Today's Range

$175.45

Now: $179.67▼

$184.17

50-Day Range

$140.25

MA: $150.56▼

$179.89

52-Week Range

$48.78

Now: $179.67▼

$184.17

Volume550,774 shs

Average Volume1.04 million shs

Market Capitalization$18.03 billion

P/E RatioN/A

Dividend YieldN/A

BetaN/A

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. Its company offers chromium instruments, enzymes, microfluidic chips, slides, reagents, and other consumable products. The company's single cell solution runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell ATAC for measuring epigenetics, including the physical organization of DNA; single cell CNV for measuring cellular heterogeneity through DNA changes, such as copy number variation; and visium spatial gene expression solution that measures the spatial gene expression patterns across a tissue sample. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10X Genomics, Inc. in November 2014. 10x Genomics, Inc. was founded in 2012 and is headquartered in Pleasanton, California.

Overall MarketRank^™

1.20 out of 5 stars

1.4 Analyst's Opinion

Consensus Rating
10x Genomics has received a consensus rating of Buy. The company's average rating score is 2.88, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $134.90, 10x Genomics has a forecasted downside of 24.9% from its current price of $179.67.
Amount of Analyst Coverage
10x Genomics has only been the subject of 2 research reports in the past 90 days.

3.1 Community Rank

Outperform Votes
10x Genomics has received 5 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
10x Genomics has received 3 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
10x Genomics has received 62.50% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about 10x Genomics and other stocks. Vote “Outperform” if you believe TXG will outperform the S&P 500 over the long term. Vote “Underperform” if you believe TXG will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
10x Genomics does not currently pay a dividend.
Dividend Growth
10x Genomics does not have a long track record of dividend growth.

0.8 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, 10x Genomics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $24,117,571.00 in company stock.
Percentage Held by Insiders
Only 13.28% of the stock of 10x Genomics is held by insiders.
Percentage Held by Institutions
60.80% of the stock of 10x Genomics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for 10x Genomics are expected to grow in the coming year, from ($1.05) to ($0.38) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of 10x Genomics is -174.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of 10x Genomics is -174.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
10x Genomics has a P/B Ratio of 41.21. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Analytical instruments

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:TXG

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.10xgenomics.com

Phone925 401 7300

Employees584

Debt

Debt-to-Equity RatioN/A

Current Ratio3.70

Quick Ratio3.52

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$245.89 million

Price / Sales73.33

Cash FlowN/A

Price / Cash FlowN/A

Book Value$4.36 per share

Price / Book41.21

Profitability

EPS (Most Recent Fiscal Year)($0.80)

Net Income$-31,250,000.00

Net Margins-31.06%

Return on Equity-19.18%

Return on Assets-13.01%

Miscellaneous

Outstanding Shares100,359,000

Market Cap$18.03 billion

Next Earnings Date2/16/2021 (Estimated)

OptionableOptionable

$179.67

-0.22 (-0.12 %)

(As of 01/15/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive TXG News and Ratings via Email

Sign-up to receive the latest news and ratings for TXG and its competitors with MarketBeat's FREE daily newsletter.

10x Genomics (NASDAQ:TXG) Frequently Asked Questions

How has 10x Genomics' stock price been impacted by COVID-19?

10x Genomics' stock was trading at $60.76 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, TXG shares have increased by 195.7% and is now trading at $179.67.
View which stocks have been most impacted by COVID-19.

Is 10x Genomics a buy right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for 10x Genomics in the last year. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" 10x Genomics stock.
View analyst ratings for 10x Genomics or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than 10x Genomics?

Wall Street analysts have given 10x Genomics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but 10x Genomics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is 10x Genomics' next earnings date?

10x Genomics is scheduled to release its next quarterly earnings announcement on Tuesday, February 16th 2021.
View our earnings forecast for 10x Genomics.

How were 10x Genomics' earnings last quarter?

10x Genomics, Inc. (NASDAQ:TXG) released its quarterly earnings results on Tuesday, November, 10th. The company reported ($0.33) earnings per share for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.33). The business earned $71.82 million during the quarter, compared to analyst estimates of $62.71 million. 10x Genomics had a negative return on equity of 19.18% and a negative net margin of 31.06%.
View 10x Genomics' earnings history.

What price target have analysts set for TXG?

8 brokerages have issued 1 year target prices for 10x Genomics' shares. Their forecasts range from $85.00 to $195.00. On average, they anticipate 10x Genomics' share price to reach $134.90 in the next year. This suggests that the stock has a possible downside of 24.9%.
View analysts' price targets for 10x Genomics or view Wall Street analyst' top-rated stocks.

Who are some of 10x Genomics' key competitors?

Some companies that are related to 10x Genomics include Illumina (ILMN), Agilent Technologies (A), Mettler-Toledo International (MTD), (BIO.B) (BIO.B), Bio-Rad Laboratories (BIO), Avantor (AVTR), Waters (WAT), PerkinElmer (PKI), Bruker (BRKR), Pacific Biosciences of California (PACB), Berkeley Lights (BLI), Coherent (COHR), Quanterix (QTRX), Bionano Genomics (BNGO) and Accelerate Diagnostics (AXDX).
View all of TXG's competitors.

Who are 10x Genomics' key executives?

10x Genomics' management team includes the following people:

Dr. Serge Saxonov Ph.D., Co-Founder, CEO & Director (Age 44, Pay $551.25k)
Dr. Benjamin J. Hindson Ph.D., Co-Founder, Pres, Chief Scientific Officer & Director (Age 46, Pay $426.51k)
Mr. Justin J. McAnear, Chief Financial Officer (Age 46, Pay $399.75k)
Mr. Eric S. Whitaker, Gen. Counsel (Age 54, Pay $416.74k)
Mr. Paul W. Wyatt, VP of Operations
Mr. Jonathan Schimmel, VP of Global Support & Sales Operations
Mr. Sam Ropp, Sr. VP of Global Sales
Mr. Edwin Hauw, VP of Marketing
Ms. Jean M. Philibert, Chief People Officer (Age 61)
Mr. Michael Schnall-Levin, Sr. VP of R&D & Founding Scientist

When did 10x Genomics IPO?

(TXG) raised $297 million in an initial public offering (IPO) on Thursday, September 12th 2019. The company issued 9,000,000 shares at a price of $31.00-$35.00 per share. J.P. Morgan, Goldman Sachs and BofA Merrill Lynch acted as the underwriters for the IPO and Cowen was co-manager.

What is 10x Genomics' stock symbol?

10x Genomics trades on the NASDAQ under the ticker symbol "TXG."

Who are 10x Genomics' major shareholders?

10x Genomics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Hamilton Lane Advisors LLC (0.08%) and IFM Investors Pty Ltd (0.01%). Company insiders that own 10x Genomics stock include Associates Vi LP Venrock, Benjamin J Hindson, Bryan E Roberts, Foresite Capital Fund I, LP, Foresite Capital Management I,, John R Stuelpnagel, Justin J Mcanear and Serge Saxonov.
View institutional ownership trends for 10x Genomics.

Which major investors are buying 10x Genomics stock?

TXG stock was purchased by a variety of institutional investors in the last quarter, including Hamilton Lane Advisors LLC, and IFM Investors Pty Ltd. Company insiders that have bought 10x Genomics stock in the last two years include Bryan E Roberts, and Foresite Capital Fund I, LP.
View insider buying and selling activity for 10x Genomics or or view top insider-buying stocks.

How do I buy shares of 10x Genomics?

Shares of TXG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is 10x Genomics' stock price today?

One share of TXG stock can currently be purchased for approximately $179.67.

How big of a company is 10x Genomics?

10x Genomics has a market capitalization of $18.03 billion and generates $245.89 million in revenue each year. The company earns $-31,250,000.00 in net income (profit) each year or ($0.80) on an earnings per share basis. 10x Genomics employs 584 workers across the globe.

What is 10x Genomics' official website?

The official website for 10x Genomics is www.10xgenomics.com.

How can I contact 10x Genomics?

10x Genomics' mailing address is 6230 STONERIDGE MALL ROAD, PLEASANTON CA, 94588. The company can be reached via phone at 925 401 7300 or via email at [email protected]

This page was last updated on 1/16/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here